Stories of change
Lillia is transforming chronic disease management. With AI precision and human empathy, we empower people to take control of their health—one micro-change at a time.
Mr. Ar*****: Reversing diabetes naturally
Mr. Ar*****: Reversing diabetes naturally
"From HbA1c 12.6% to 5.7% in 3 months – without allopathic medicines!"
Struggling with uncontrolled diabetes, weight gain, and chronic pain, Mr. Ar***** turned his life around with Lillia’s tech-powered solutions like continuous glucose monitoring. He shed 9 kg and resolved lethargy and skin allergies, proving the power of personalized, non-invasive care.
Client speak
“We are thrilled to collaborate with Lillia in our mission to lower diabetes rates and reduce healthcare costs for over 15,000 QLM members managing the condition. As we advance toward our vision of transforming healthcare from ‘Illness to Wellness,’ we eagerly anticipate the innovative AI-driven health solutions and systems they are developing.”
Mohammed Salem,
Chief Business Officer, QLM Life and Medical Insurance, Qatar
Best-in-class clinical impact
PHCC, Qatar: Largest diabetes management study in GCC
Published by American Diabetes
Association (ADA) Cohort of 633
patients across 27 Primary Health
Care Corporation (PHCC) clinics
Outcome highlights
- Reduction in HbA1c:
0.91% reduction for patients with
initial HbA1c ≥ 8 - Reduction in blood pressure:
7.84% reduction in systolic blood
pressure for patients
with initial BP ≥ 130/80 - Reduction in cholesterol:
0.81 mmol/L reduction in total
cholesterol for patients with
cholesterol levels ≥ 5.18 mmol/L - Reduction in weight:
0.72% reduction in BMI for
patients with initial BMI ≥ 25
India: Large-scale diabetes management study
Published by American Diabetes Association (ADA) Cohort of 808 patients across 50 cities in India
Outcome highlights
- Reduction in HbA1c:
1.10% reduction for 808 patients - Reduction in HbA1c (uncontrolled
diabetes):
2.18% reduction for patients with
initial HbA1c ≥ 9 - Increase in time in range (TIR):
7.16% increase for patients with
initial TIR of 40.3% ± 31%
Case Study: Leading clinic chain in India
Obesity and Diabetes Management Program
Outcome highlights
- Reduction in HbA1c:
1.40% average reduction - Reduction in BMI:
3.35 average reduction for most compliant users - Reduction in weight:
3.50kg average reduction